Evidence map›Paper›PMID 40750617›Full record

ArticleNature communications2025

Structural convergence and water-mediated substrate mimicry enable broad neuraminidase inhibition by human antibodies.

Julia Lederhofer, Andrew J Borst, Lam Nguyen, Rebecca A Gillespie, Connor J Williams, Emma L Walker, Julie E Raab, Christina Yap, Daniel Ellis, Adrian Creanga and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Julia Lederhofer *Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0001-9096-9701
Andrew J Borst *Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA.ORCID http://orcid.org/0000-0003-4297-7824
Lam NguyenVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Rebecca A GillespieVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0001-5741-3699
Connor J WilliamsDepartment of Immunology, Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
Emma L WalkerDepartment of Immunology, Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0009-0007-6867-211X
Julie E RaabVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Christina YapVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Daniel EllisInstitute for Protein Design, University of Washington, Seattle, WA, 98195, USA.
Adrian CreangaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0002-3087-8397
Hyon-Xhi TanDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Thi H T DoDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Michelle RavichandranVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0009-0005-9600-0551
Adrian B McDermottVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0003-0616-9117
Valerie Le SageDepartment of Immunology, Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
Sarah F AndrewsVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0002-2583-1949
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Adam K WheatleyDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.ORCID http://orcid.org/0000-0002-5593-9387
Douglas S ReedDepartment of Immunology, Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-0076-9023
Neil P KingInstitute for Protein Design, University of Washington, Seattle, WA, 98195, USA. neilking@uw.edu.ORCID http://orcid.org/0000-0002-2978-4692
Masaru KanekiyoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA. kanekiyom@nih.gov.ORCID http://orcid.org/0000-0001-5767-1532

Funding

Influenza Vaccine Research and DevelopmentZIAAI005003 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KANEKIYO, MASARU · 2009 to 2025
$89.8M
Practices CoreUC7AI180311 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI William Paul Duprex · 2023 to 2026
$13.2M
ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
Department of Health | National Health and Medical Research Council (NHMRC) GNT1173433Department of Health | National Health and Medical Research Council (NHMRC) GNT2009711Intramural NIH HHS ZIA AI005003NIAID NIH HHS UC7 AI180311NIGMS NIH HHS R01 GM129325U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) ZIAAI005003
6 · The paper itself

Abstract

Influenza has been responsible for multiple global pandemics and seasonal epidemics and claimed millions of lives. The imminent threat of a panzootic outbreak of avian influenza H5N1 virus underscores the urgent need for pandemic preparedness and effective countermeasures, including monoclonal antibodies (mAbs). Here, we characterize human mAbs that target the highly conserved catalytic site of viral neuraminidase (NA), termed NCS mAbs, and the molecular basis of their broad specificity. Cross-reactive NA-specific B cells were isolated by using stabilized NA probes of non-circulating subtypes. We found that NCS mAbs recognized multiple NAs of influenza A as well as influenza B NAs and conferred prophylactic protections in mice against H1N1, H5N1, and influenza B viruses. Cryo-electron microscopy structures of two NCS mAbs revealed that they rely on structural mimicry of sialic acid, the substrate of NA, by coordinating not only amino acid side chains but also water molecules, enabling inhibition of NA activity across multiple influenza A and B viruses, including avian influenza clade 2.3.4.4b H5N1 viruses. Our results provide a molecular basis for the broad reactivity and inhibitory activity of NCS mAbs targeting the catalytic site of NA through substrate mimicry.

Indexed as

Antibodies, MonoclonalAntibodies, ViralNeuraminidaseViral ProteinsAnimalsCatalytic DomainCross ReactionsCryoelectron MicroscopyFemaleHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza B virusInfluenza, HumanMiceMice, Inbred BALB CAntibodies, MonoclonalAntibodies, ViralNeuraminidaseViral ProteinsWater

Identifiers

PMID40750617
PMCPMC12316982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.